Patients with positive HER-2 amplification advanced gastroesophageal junction cancer achieved complete response with combined chemotherapy of AK104/cadonilimab (PD-1/CTLA-4 bispecific): A case report

BACKGROUND: Human epidermal growth factor receptor 2 (HER2) is the most prominent therapeutic target for advanced gastric (G)/GEJ cancer. However, targeted therapy did not significantly improve survival. Currently, there are no regimens for the treatment of HER-2 amplification that exclude targeted...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Jieqiong, Zhu, Qiang, Peng, Ziru, Chen, Zhen, Liu, Yuantao, Liu, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773983/
https://www.ncbi.nlm.nih.gov/pubmed/36569905
http://dx.doi.org/10.3389/fimmu.2022.1049518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773983/
https://www.ncbi.nlm.nih.gov/pubmed/36569905
http://dx.doi.org/10.3389/fimmu.2022.1049518

Ejemplares similares